[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635917":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":11,"studyPopulation":11,"armGroups":41,"interventions":48,"overallOfficials":53,"centralContacts":58,"locations":66,"responsibleParty":81,"collaborators":11,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":11,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":11,"enrollmentInfo":92,"targetDuration":11,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants With Adverse Events (AEs)",null,"Up to approximately 2 years",[14,16,18,20,22,24,26,28,30,33],{"measure":15,"description":11,"timeFrame":12},"Serum Concentration of RO7851624",{"measure":17,"description":11,"timeFrame":12},"Objective Response Rate (ORR)",{"measure":19,"description":11,"timeFrame":12},"Complete Response (CR) Rate\u002F Stringent Complete Response (sCR) Rate)",{"measure":21,"description":11,"timeFrame":12},"Rate of Very Good Partial Response (VGPR) Rate or Better",{"measure":23,"description":11,"timeFrame":12},"Progression-Free Survival (PFS)",{"measure":25,"description":11,"timeFrame":12},"Duration of Response (DOR)",{"measure":27,"description":11,"timeFrame":12},"Time to First Response",{"measure":29,"description":11,"timeFrame":12},"Time to Best Response",{"measure":31,"description":11,"timeFrame":32},"Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7851624 at Baseline and During the Study","Baseline, up to approximately 2 years",{"measure":34,"description":11,"timeFrame":12},"Recommended Dose and Regimen of RO7851624",{"allocation":36,"interventionModel":37,"interventionModelDescription":11,"primaryPurpose":38,"observationalModel":11,"timePerspective":11,"maskingInfo":39},"NA","SINGLE_GROUP","TREATMENT",{"masking":40,"maskingDescription":11,"whoMasked":11},"NONE",[42],{"label":43,"type":44,"description":45,"interventionNames":46},"RO7851624","EXPERIMENTAL","Participants will receive RO7851624 in a dose escalation stage followed by a dose expansion stage.",[47],"Drug: RO7851624",[49],{"type":50,"name":43,"description":51,"armGroupLabels":52,"otherNames":11},"DRUG","Participants will receive RO7851624 as per the schedule described in the protocol.",[43],[54],{"name":55,"affiliation":56,"role":57},"Clinical Trials","Hoffmann-La Roche","STUDY_DIRECTOR",[59,64],{"name":60,"role":61,"phone":62,"phoneExt":11,"email":63},"Reference Study ID Number: GO46140 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":65,"role":61,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[67],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":11},"Peter MacCallum Cancer Center","RECRUITING","Parkville","Victoria","3052","Australia","AU",{"type":76,"coordinates":77},"Point",[78,79],144.95,-37.78333,{"lat":79,"lon":78},{"type":82,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635917","phase-1-a-study-to-evaluate-ro7851624-in-participants-with-relapsedrefractory-multiple-myeloma-rrmm-100635917",false,"NCT07558915","A Study to Evaluate RO7851624 in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)","An Open-Label, Multicenter, Phase Ia\u002Fb Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Life expectancy of at least 12 weeks.\n* Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.\n* Measurable disease.\n\nExclusion Criteria:\n\n* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment.\n* Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.\n* Prior allogeneic SCT.\n* Prior solid organ transplantation.","ALL","18 Years",{"count":93,"type":94},160,"ESTIMATED","INTERVENTIONAL",[97],"PHASE1","This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \\[PIs\\], immunomodulators \\[IMiDs\\], and anti-cluster of differentiation 38 \\[anti-CD38\\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.",[100],"Relapsed\u002FRefractory Multiple Myeloma","2026-10-08",{"date":103,"type":104},"2026-10-09","ACTUAL",{"date":106,"type":104},"2026-06-23",{"date":108,"type":94},"2031-10-01",{"name":5,"class":6},1]